The purpose of the current study was to assess the association between HOXA9 (homeobox A9) promoter methylation and head and neck squamous cell carcinoma (HNSCC) and its diagnostic value.
| INTRODUC TI ON
Worldwide, head and neck cancer is the sixth most common malignancy and fifth leading cause of cancer-related death. 1 More than 90% of head and neck tumors are squamous cell carcinomas (HNSCC) arising from the epithelial mucosal membranes of the upper aerodigestive tract (oral and nasal cavity, oropharynx, hypopharynx, and larynx). 2 Besides established risk factors (tobacco and alcohol abuse), high-risk human papillomavirus (HPV) infection has recently been reported as an independent risk factor for a subset of HNSCC. 3, 4 According to recently epidemiological data from the American Cancer Society, 64 690 new cases of HNSCC and at least 13 740 deaths are projected to occur in the United States in 2018, 5 which is consistent with a continued rising trend over recent years. 6, 7 As early-stage HNSCC is often symptomless, the majority of HNSCC patients are diagnosed with advanced stage disease, including lymphatic metastasis and distant metastasis, and the 5-year survival rate remains <50%, 8 while outcomes and quality of life can be remarkably improved if HNSCC is detected at an early stage. 9 In addition, biopsy by laryngoscope, which often requires general anesthesia, is considered the gold standard method for HNSCC diagnosis; the lack of a similarly valuable, non-invasive and cost-effective method for screening and early diagnosis of this disease is considered the major obstacle to improving the prognosis of HNSCC.
Hence, identification of effective biomarkers for early HNSCC is an urgent priority for individual diagnosis and therapy.
Head and neck squamous cell carcinoma is a complex disease that can affect multiple sites and is caused by intricate interactions among genetic susceptibility, epigenetic modification, and environmental factors. 10 Emerging evidence indicates that epigenetic inactivation of tumor suppressor genes (TSGs) resulting from promoter methylation is involved in the onset and progress of various cancers, including esophageal squamous cell carcinoma, 11 cervical cancer, 12 lung cancer, 13 and breast cancer. 14 Aberrant methylation events are frequent, chemically stable, and relatively early molecular changes during carcinogenesis, 15, 16 which have potential as biomarkers for cancer screening and early diagnosis. 17, 18 Homeobox (HOX) genes are a highly conserved family of 39 transcription factors that are grouped into four clusters, HOXA through HOXD. 19, 20 HOX genes regulate and determine different cell types during embryonic development. 20, 21 In addition, there is increasing evidence that HOX genes have important functions in regulation of the delicate balance between cell proliferation and differentiation during cancer development. 22, 23 The HOXA9 gene, mapping to chromosome 7p15.2, is a member of this large family, and its abnormal expression is involved in the emergence of numerous solid and hematopoietic malignancies. HOXA9 is frequently activated in hematopoietic malignancies 24 ; however, it can be downregulated in solid tumors, 25, 26 particularly squamous cell carcinoma. Recent studies have revealed that hypermethylation of the HOXA9 promoter leads to its transcriptional inactivation in several of cancers, including those of the lung, 28 breast, 29 cervix, 25 and bladder 30 ; however, the relationship between HOXA9 and HNSCC remains unclear.
In the present study, we investigated the association between HOXA9 promoter methylation in 145 HNSCC patients and its potential diagnostic value. Furthermore, data from 578 samples available from the Cancer Genome Atlas (TCGA) database were analyzed to validate our findings. Bisulfite-converted DNA was stored in tris-ethylenediaminetetraacetic acid buffer for subsequent methylation analysis.
| MATERIAL S AND ME THODS

| Specimens and clinical data collection
| DNA extraction and bisulfite conversion
| Quantitative methylation-specific polymerase chain reaction (qMSP)
Methylation levels of the HOXA9 promoter (chr7:27206577-27206704) in 145 HNSCC and paired adjacent tissue samples were determined using a qMSP assay as described previously. 31 ACTB was chosen as the internal control 28 and human methylated DNA ( were used to evaluate HOXA9 methylation in this dataset. Receiver operating characteristic (ROC) analysis was used to assess the diagnostic value of HOXA9 methylation for HNSCC. A two-tailed P value <0.05 was defined as statistically significant.
| Statistical analysis
| RE SULTS
In the current study, 145 HNSCC and corresponding non-tumor tis- In our study cohort, we found that the HOXA9 methylation levels in tumor tissues were significantly higher than those in paired Figure 2A ).
Subsequently, we determined HOXA9 methylation levels using data from TCGA database. As shown in Figure 2B , this analysis validated our finding that there was a significant difference in HOXA9 methyl- Based on these findings, we analyzed the association between HOXA9 methylation levels, its expression levels, and the clinicopathological characteristics of patients with HNSCC, including age, gender, smoking behavior, histological classification, tumor location, T classification, lymph metastasis, and tumor stage. As shown in Table 1 , HOXA9 hypermethylation in human HNSCC tissues was associated with T classification (P = 0.008), lymph metastasis (P = 0.012), and tumor stage (P = 0.004). Importantly, these findings were replicated by analysis of TCGA data. HOXA9 was significantly hypermethylated in patients with advanced pathologic tumors (P = 0.041), advanced pathologic nodal category (P = 0.047), and advanced pathologic stage (P = 0.009) ( Table 2) . Additionally, a borderline significant difference in HOXA9 methylation status was identified between male and female patients in TCGA data (P = 0.06).
This may be explained in part by differences in smoking habits, with female patients mainly being non-smokers; however, no statistically significant correlation was identified with any other clinicopathological characteristic in either our study cohort or the TCGA cohort.
Sensitivity and specificity are objective and easy to understand; however, they are often affected by the use of different threshold values. We examined the diagnostic value of HOXA9 promoter methylation in HNSCC using ROC curve analysis, which is a synthe- Figure 3A ). In the TCGA cohort, HOXA9 hypermethylation yielded an AUC of 0.967 (95% CI: 0.952-0.983), a sensitivity of 93.6%, and a specificity of 92.0% with a cutoff value of 0.343 ( Figure 3B ). The difference in HOXA9 promoter methylation between these groups was significant.
| D ISCUSS I ON
malignancies as part of the process of carcinogenesis. 34 Compared with other molecular markers, DNA hypermethylation is a common and early event during the progression of various tumors and it is chemically and biologically more stable than RNA or the majority of proteins. 35 Given these advantages and the development of technology for their detection, methylation biomarkers have great potential for use in early screening and diagnosis of cancer. 36 
HOXA9
functions as a tumor suppressor gene that suppresses breast tumor growth and metastasis. 23 Furthermore, methylation of the HOXA9 promoter is associated with progression and prognosis in numerous cancers. 28, 29 In the current study, we recruited 145 HNSCC patients to investigate the association of HOXA9 methylation with HNSCC and its potential for use in detection of HNSCC. Our results showed that methylation levels of the HOXA9 promoter were significantly higher in HNSCC than adjacent non-tumor tissues. Similarly, further bioinformatics analyses of TCGA data confirmed that HOXA9 methylation was higher in HNSCC compared with normal tissues. Taken together, these findings suggest that HOXA9 methylation is a risk factor for HNSCC and has potential value for its diagnosis.
Subsequently, we also determined the association between HOXA9 promoter methylation and the clinicopathological characteristics of patients with HNSCC. Tumor invasion and clinical stage are vital factors for assessing prognosis in patients with cancer and are among the most common tools used for that purpose. 37, 38 In our qMSP study, we demonstrated a significantly elevated frequency of HOXA9 promoter methylation in patients with advanced tumor stage and advanced clinical stage, which was confirmed by analysis of TCGA data. Overall, these results suggest that HOXA9 methylation may be involved in the progression and metastasis of HNSCC. Given the well-developed lymphatic network in the neck region, HNSCC has a high propensity to undergo lymph node metastasis 40 ; however, because of the high incidence of occult lymph node metastasis, 41 the accurate diagnosis of lymph node metastases remains challenging.
Analyses of both our cohort and TCGA data showed that HOXA9 promoter methylation levels were significantly higher in HNSCC patients with lymph node metastasis compared with those without, providing a potential means to distinguish HNSCC patients with lymphatic metastasis. Additionally, an almost statistically significant difference in HOXA9 methylation status was found between male and female patients in TCGA data (P = 0.06), which may be partly attributable to differences in smoking habits, with female patients mainly being non-smokers.
Therapeutic procedures and prognosis differ substantially be- fluids (blood, bronchial aspirates, brushing, saliva, and urine). 46, 47 In the present study, we constructed ROC curves and calculated the AUC to determine the diagnostic value of HOXA9 methylation for HNSCC.
The AUC values were close to 1.0, signifying near perfect diagnostic power. The AUC for our study was 0.930 and that based on TCGA data was even more encouraging at 0.967, indicating that HOXA9 promoter methylation has excellent diagnostic accuracy for HNSCC.
The current study had some limitations. A number of methods have been developed to assess biomarkers in biological fluids to non-invasively identify early HNSCC. 49, 50 Due to a lack of blood and/ or saliva samples, we were unable to explore the diagnostic value of non-invasive detection of HNSCC methylation. In addition, emerging evidence indicates that a panel of several methylation genes could improve cancer diagnosis, 51 while our study focused on a single gene, which may not completely satisfy the requirements for clinical application. Therefore, future investigation is needed to determine whether a panel for analysis of the HOXA9 promoter combined with other epigenetic biomarkers will be of higher diagnostic value, particularly using liquid biopsies.
| CON CLUS ION
In conclusion, HOXA9 promoter hypermethylation is associated with the risk for HNSCC and its progression and metastasis. Additionally, HOXA9 hypermethylation has potential for use as a biomarker for the early diagnosis and screening of patients with HNSCC. The difference of HOXA9 promoter methylation between these groups was significant.
